These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 666453)

  • 1. Effect of p-chloramphetamine on the inactivation of monoamine oxidase in rat brain by 3-amino-2-oxazolidinone, 2-hydroxyethylhydrazine and pheylisopropylhydrazine.
    Fuller RW; Roush BW
    Arch Int Pharmacodyn Ther; 1978 Mar; 232(1):134-40. PubMed ID: 666453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of monoamine oxidase A and B by two substrate-analogues, 5-fluoro-alpha-methyltryptamine and p-chloro-beta-methylphenethylamine.
    Kinemuchi H; Arai Y
    Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):125-8. PubMed ID: 3797802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of monoamine oxidase by 3-amino-2-oxazolidinone and 2-hydroxy-ethylhydrazine.
    Fuller RW; Roush BW
    Experientia; 1971 Jul; 27(7):774-5. PubMed ID: 5139485
    [No Abstract]   [Full Text] [Related]  

  • 4. Inability of imipramine to protect against type A or type B monoamine oxidase inhibition by pargyline.
    Fuller RW; Hemrick SK
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):411-4. PubMed ID: 461967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further studies on the effects of N-cyclopropyl-p-chloroamphetamine in rat brain.
    Fuller RW; Perry KW
    Neuropharmacology; 1977; 16(7-8):495-7. PubMed ID: 917253
    [No Abstract]   [Full Text] [Related]  

  • 6. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 2-(p-chlorophenyl)cyclopropylamine on 5-hydroxyindole concentration and monoamine oxidase activity in rat brain.
    Fuller RW; Kaiser C
    Biochem Pharmacol; 1980 Dec; 29(24):3328-30. PubMed ID: 6163433
    [No Abstract]   [Full Text] [Related]  

  • 8. Irreversible inhibition of monoamine oxidase.
    Planz G; Quiring K; Palm D
    Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):424-5. PubMed ID: 4253849
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone.
    Hoogenboom LA; Tomassini O; Oorsprong MB; Kuiper HA
    Food Chem Toxicol; 1991 Mar; 29(3):185-91. PubMed ID: 2032659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on monoamine oxidase. 5. Enzymic differences in the monoamine oxidases in the brain and liver].
    Tatsuo F
    Nihon Yakurigaku Zasshi; 1968 Jul; 64(4):393-8. PubMed ID: 4387722
    [No Abstract]   [Full Text] [Related]  

  • 11. Different action of 5-hydroxytryptamine (5-HT) uptake inhibitors on fenfluramine- but not p-chloramphetamine-induced hyperthermia in rats.
    Paełowski L
    J Pharm Pharmacol; 1981 Aug; 33(8):538-40. PubMed ID: 6115932
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible involvement of dopamine in the long-term serotonin depletion by p-chloroamphetamine and beta,beta-difluoro-p-chloroamphetamine in rats.
    Henderson MG; Perry KW; Fuller RW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):417-24. PubMed ID: 8229770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of monoamine oxidase by substituted hydrazines.
    Tipton KF
    Biochem J; 1972 Jul; 128(4):913-9. PubMed ID: 4674124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative data on the inhibition of the monoaminoxidase activity by the hydrazine group substances].
    Riabokon' NA; Grebennik LI
    Farmakol Toksikol; 1965; 28(5):608-12. PubMed ID: 5875829
    [No Abstract]   [Full Text] [Related]  

  • 15. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
    Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
    J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible and irreversible effects of p-chloroamphetamine on brain serotonin in mice.
    Steranka L; Bessent R; Sanders-Bush E
    Commun Psychopharmacol; 1977; 1(5):447-54. PubMed ID: 606480
    [No Abstract]   [Full Text] [Related]  

  • 17. Tissue monoamine oxidase inhibitions by convulsigenic doses of hydrazines and related B6-hydrazones. SAM-TR-66-79.
    Wykes AA
    Tech Rep SAM-TR; 1966 Sep; ():1-11. PubMed ID: 5297194
    [No Abstract]   [Full Text] [Related]  

  • 18. Antagonism between long acting monoamine oxidase inhibitors (MAOI) and MD780515, a new specific and reversible MAOI.
    Kan JP; Benedetti MS
    Life Sci; 1980 Jun; 26(25):2165-71. PubMed ID: 7401915
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of various antidepressive agents on brain monoamine oxidase activity].
    Gankina EM; Moskvitina TA; Gorkin VZ; Val'dman AV
    Biull Eksp Biol Med; 1982 Nov; 94(11):29-31. PubMed ID: 7150732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
    Fuller RW
    Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.